Analyst Activity – Royal Bank of Canada Reiterates Buy on Abeona Therapeutics (NASDAQ:ABEO)

Analyst Ratings For Abeona Therapeutics (NASDAQ:ABEO)

Today, Royal Bank of Canada reiterated its Buy rating on Abeona Therapeutics (NASDAQ:ABEO) with a price target of $26.00.

Some recent analyst ratings include

  • 1/24/2018-Royal Bank of Canada Reiterated Rating of Buy.
  • 11/22/2017-Jefferies Group Reiterated Rating of Buy.
  • 11/8/2017-SunTrust Banks initiated coverage with a Buy rating.
  • 10/10/2017-Citigroup initiated coverage with a Buy rating.

Recent Insider Trading Activity For Abeona Therapeutics (NASDAQ:ABEO)
Abeona Therapeutics (NASDAQ:ABEO) has insider ownership of 6.80% and institutional ownership of 41.97%.

  • On 9/20/2016 Todd Wider, Director, bought 5,000 with an average share price of $5.48 per share and the total transaction amounting to $27,400.00.
  • On 7/31/2015 Mark J Ahn, Director, bought 18,182 with an average share price of $5.50 per share and the total transaction amounting to $100,001.00.
  • On 1/26/2015 Mark J Ahn, Director, bought 25,000 with an average share price of $4.00 per share and the total transaction amounting to $100,000.00.
  • On 12/24/2014 Steven H Rouhandeh, Director, bought 250,000 with an average share price of $4.00 per share and the total transaction amounting to $1,000,000.00.

Recent Trading Activity for Abeona Therapeutics (NASDAQ:ABEO)
Shares of Abeona Therapeutics closed the previous trading session at 15.90 up +0.50 3.25% with shares trading hands.

An ad to help with our costs